About PD-1 Inhibitors PD-1 inhibitors work by blocking the PD-1 (programmed death-1) receptor on T cells, preventing cancer cells from evading the immune system and restoring the body’s ability to ...

Indaptus advanced its Decoy20 trial to test a combination with tislelizumab, aiming to enhance checkpoint inhibitor effectiveness in cancer treatment.

Antitumor activity observed with confirmed partial responses in 50% of patientsat highest dose tested to date, across ...

Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an ...

TG Therapeutics, Inc.’s TGTX share price has surged by 10.20%, which has investors questioning if this is right time to sell.

Nature's Toolbox (NTx), a life sciences company developing next-generation platforms for RNA and protein manufacturing, today announced the founding of its Scientific Advisory Board (SAB) with ...

Checkpoint Therapeutics (NASDAQ:CKPT – Get Free Report)‘s stock had its “neutral” rating reissued by research analysts at HC ...

Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.

Checkpoint Therapeutics (NASDAQ:CKPT – Get Free Report)‘s stock had its “hold” rating reiterated by equities research ...

Fintel reports that on March 11, 2025, HC Wainwright & Co. downgraded their outlook for Checkpoint Therapeutics ...

Fintel reports that on March 10, 2025, Lake Street downgraded their outlook for Checkpoint Therapeutics (NasdaqCM:CKPT) from ...

Compass Therapeutics, Inc.’s CMPX share price has dipped by 11.90%, which has investors questioning if this is right time to buy.